Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

The Lancet

Volumn 389, Issue 10080, 2017, Pages 1699-1709

  Feagan, Brian G ^a   Sandborn, William J ^b   D'Haens, Geert ^c   Panés, Julián ^d   Kaser, Arthur ^e   Ferrante, Marc ^f   Louis, Edouard ^g   Franchimont, Denis ^h   Dewit, Olivier ⁱ   Seidler, Ursula ^j   Kim, Kyung Jo ^k   Neurath, Markus F ^l   Schreiber, Stefan ^m   Scholl, Paul ⁿ   Pamulapati, Chandrasena ⁿ   Lalovic, Bojan ⁿ   Visvanathan, Sudha ⁿ   Padula, Steven J ^o   Herichova, Ivona ^p   Soaita, Adina ⁿ   Hall, David B ⁿ   Böcher, Wulf O ^o   more..

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO HEALTH SYSTEM   (United States)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g UNIVERSITY OF LIÈGE   (Belgium)

^h ERASME HOSPITAL   (Belgium)

ⁱ CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^j HANNOVER MEDICAL SCHOOL   (Germany)

^k Asan Medical Center   (South Korea)

^l UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^m UNIVERSITY OF KIEL   (Germany)

ⁿ BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^o BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^p BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOMODULATING AGENT; PLACEBO; RISANKIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; GASTROINTESTINAL AGENT; IL23A PROTEIN, HUMAN; INTERLEUKIN 23P19; MONOCLONAL ANTIBODY;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; COLONOSCOPY; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; CROHN DISEASE ENDOSCOPIC INDEX OF SEVERITY; DISABILITY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG WITHDRAWAL; EUROPE; FEMALE; HEADACHE; HUMAN; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NORTH AMERICA; OSTEOMYELITIS; OUTCOME ASSESSMENT; PERIANAL ABSCESS; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REMISSION; SOUTHEAST ASIA; VOMITING; ADOLESCENT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INTERLEUKIN-23 SUBUNIT P19; MALE; MIDDLE AGED; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85017435425     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)30570-6     Document Type: Article

References (35)

1. 1 Baumgart, DC, Sandborn, WJ, Crohn's disease. Lancet 380 (2012), 1590–1605.
2. 2 Sandborn, WJ, Feagan, BG, Stoinov, S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 357 (2007), 228–238.
3. 3 Targan, SR, Feagan, BG, Fedorak, RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 132 (2007), 1672–1683.
4. 4 Peyrin-Biroulet, L, Deltenre, P, de Suray, N, Branche, J, Sandborn, WJ, Colombel, JF, Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastro Hepatol 6 (2008), 644–653.
5. 5 Gordon, JP, McEwan, PC, Maguire, A, Sugrue, DM, Puelles, J, Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveys. Eur J Gastroenterol Hepatol 27 (2015), 804–812.
6. 6 Lichtenstein, GR, Sbreu, MT, Cohen, R, Tremaine, W, American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Rev Gastroenterol Mex 71 (2006), 351–401.
7. 7 Neurath, MF, IL-23: a master regulator in Crohn disease. Nat Med 13 (2007), 26–28.
8. 8 Duerr, RH, Taylor, KD, Brant, SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314 (2006), 1461–1463.
9. 9 Geremia, A, Arancibia-Carcamo, CV, Fleming, MP, et al. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med 208 (2011), 1127–1133.
10. 10 Campa, M, Mansouri, B, Warren, R, Menter, A, A review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis. Dermatol Ther 6 (2016), 1–12.
11. 11 Sandborn, WJ, Gasink, C, Gao, LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 367 (2012), 1519–1528.
12. 12 Feagan, BG, Sandborn, WJ, Gasink, C, et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 375 (2016), 1946–1960.
13. 13 Hueber, W, Sands, BE, Lewitzky, S, et al. Secikunmab, a human anti-IL-17a monoclonal antibody, for moderate to severe Crohn's disease: unpected results of a randomised, double-blind placebo-controlled trial. Gut 61 (2012), 1693–1700.
14. 14 Targan, SR, Feagan, B, Vermeire, S, et al. A randomised, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn's disease. Am J Gastroenterol 111 (2016), 1599–1607.
15. 15 Singh, S, Kroe-Barrett, RR, Canada, KA, et al. Selective targeting of the IL23 pathway: generation and characterization of a novel high-affinity humanized anti-IL23A antibody. mAbs 7 (2015), 778–791.
16. 16 Brunda, MJ, Luistro, L, Warrier, RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178 (1993), 1223–1230.
17. 17 Stobie, L, Gurunathan, S, Prussin, C, et al. The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge. Proc Natl Acad Sci USA 97 (2000), 8427–8432.
18. 18 Krueger, JG, Ferris, LK, Menter, A, et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 136 (2015), 116–124.
19. 19 Levesque, BG, Sandborn, WJ, Ruel, J, et al. Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. Gastroenterology 148 (2015), 37–51.
20. 20 Irvine, EJ, Feagan, B, Rochon, J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 106 (1994), 287–296.
21. 21 Matsuoka, K, Kanai, T, Mechanism and therapeutic strategy of secondary failure to anti-tumor necrosis factor-alpha monoclonal antibody treatment for Crohn's disease. Digestion 88 (2013), 17–19.
22. 22 Terdiman, JP, Gruss, CB, Heidelbaugh, JJ, et al. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology 145 (2013), 1459–1463.
23. 23 Gisbert, JP, Marin, AC, McNicholl, AG, Chaparro, M, Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther 41 (2015), 613–623.
24. 24 Sandborn, WJ, Feagan, BG, Rutgeerts, P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 369 (2013), 711–721.
25. 25 Targan, SR, Hanauer, SB, van Deventer, SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337 (1997), 1029–1035.
26. 26 Hanauer, SB, Sandborn, WJ, Rutgeerts, P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130 (2006), 323–333.
27. 27 Peyrin-Biroulet, L, Reinisch, W, Colombel, JF, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut 63 (2014), 88–95.
28. 28 Rutgeerts, P, Van Assche, G, Sandborn, WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 142 (2012), 1102–1111.
29. 29 Papp, K, Blauvelt, A, Bukhalo, M, et al. Selective blockade of IL-23p19 with BI 655066 is associated with clinical responses superior to ustekinumab in patients with moderate-to-severe plaque psoriasis: Results from a 48-week Phase II study. J Am Acad Dermatol, 74(suppl 1), 2016, AB274.
30. 30 Ordas, I, Feagan, BG, Sandborn, WJ, Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin GastroHepatol 10 (2012), 1079–1087.
31. 31 Brandse, JF, van den Brink, GR, Wildenberg, ME, et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology 149 (2015), 350–355.
32. 32 Kleinschek, MA, Boniface, K, Sadekova, S, et al. Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. J Exp Med 206 (2009), 525–534.
33. 33 van Schie, KA, Wolbink, GJ, Rispens, T, Cross-reactive and pre-existing antibodies to therapeutic antibodies—effects on treatment and immunogenicity. mAbs 7 (2015), 662–671.
34. 34 Khanna, R, Bouguen, G, Feagan, BG, et al. A systematic review of measurement of endoscopic disease activity and mucosal healing in Crohn's disease: recommendations for clinical trial design. Inflamm Bowel Dis 20 (2014), 1850–1861.
35. 35 Vuitton, L, Marteau, P, Sandborn, WJ, et al. IOIBD technical review on endoscopic indices for Crohn's disease clinical trials. Gut 20 (2016), 1447–1455.